Site Feature: Puurs, Belgium

Bold Moves

Transform our go-to-market model

Unleash the power of our people

The Pfizer Global Supply (PGS) site in Puurs, Belgium, specializing in aseptic production and packaging, is one of the largest production and packaging sites in the worldwide Pfizer network

Each year, colleagues in Puurs produce more than 400 million doses of injectable vaccines and medicines in various formats including ampoules, vials, plastic bottles, syringes and cartridges for pens. These medicines are destined for patients in more than 170 countries worldwide and almost one-third of the total production in Puurs is directed to developing countries through Pfizer’s collaboration with world aid organizations such as UNICEF, WHO and GAVI.

400 million

Colleagues in Puurs produce more than 400 million doses of injectable vaccines and medicines each year.

170 ​​​​​​​countries

Injectable vaccines and medicines produced in Puurs are destined for patients in more than 170 countries worldwide.

​​​​​​The production of the Pfizer-BioNTech COVID-19 vaccine is another example of the site’s strategic importance to PGS, Pfizer and patients. Upon the initial announcement in May that Pfizer Puurs could be involved in COVID-19 vaccine production, the site immediately began preparing: investing in infrastructure, improving existing production facilities and adding new production lines. Since then, site colleagues have been moving, as they say, “at the speed of science” to manufacture doses of our COVID-19 vaccine for all markets outside the U.S.

​​​​​​The site is also known for its focus on renewable energy. It utilizes two wind turbines, solar panels and a cogeneration plant for its power and heat supply. Per year, Puurs colleagues travel more than two million kilometers commuting by bike.

Our colleagues are known for demonstrating the Pfizer values of courage and excellence every single day. We are inspired by Pfizer’s purpose – Breakthroughs that change patients’ lives – and by the impact we can have on patients around the world.”

Luc Van Steenwinkel

Puurs Site Leader, Pfizer

​​​​​​The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories